Vertex Planning Partners’s AbbVie ABBV Stock Holding History

Vertex Planning Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.28M	Buy	24,972 +10,805	+76%	+$2.32M	0.93%	25
2026 Q1	$3.08M	Buy	14,167 +14	+0.1%	+$3.11K	0.6%	35
2025 Q4	$3.23M	Sell	14,153 -1,749	-11%	-$398K	0.75%	30
2025 Q3	$3.68M	Sell	15,902 -139	-0.9%	-$28.3K	0.71%	33
2025 Q2	$2.98M	Buy	16,041 +23	+0.1%	+$4.28K	0.62%	37
2025 Q1	$3.36M	Buy	16,018 +77	+0.5%	+$15K	0.73%	29
2024 Q4	$2.83M	Buy	15,941 +5,721	+56%	+$1.05M	0.63%	33
2024 Q3	$2.02M	Buy	10,220 +18	+0.2%	+$3.36K	0.48%	34
2024 Q2	$1.75M	Sell	10,202 -82	-0.8%	-$13.6K	0.45%	34
2024 Q1	$1.87M	Sell	10,284 -3,541	-26%	-$610K	0.52%	30
2023 Q4	$2.14M	Buy	13,825 +3,032	+28%	+$442K	0.63%	21
2023 Q3	$1.61M	Buy	10,793 +513	+5%	+$75.3K	0.55%	24
2023 Q2	$1.39M	Buy	10,280 +5,320	+107%	+$780K	0.47%	35
2023 Q1	$790K	Sell	4,960 -1,742	-26%	-$266K	0.3%	48
2022 Q4	$1.08M	Buy	+6,702	New	+$1.03M	0.42%	31

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vertex Planning Partners's ABBV Position: Q2 2026 in Review

Vertex Planning Partners increased its AbbVie (ABBV) stake by 76% in Q2 2026, buying an estimated $2.32M and bringing the position to 24,972 shares worth $6.28M. The position accounts for 0.93% of the portfolio, ranked #25.

Vertex Planning Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Vertex Planning Partners held 24,972 shares of AbbVie worth $6.28M as of Q2 2026.
Vertex Planning Partners bought 10,805 AbbVie shares in Q2 2026, an estimated $2.32M.
AbbVie made up 0.93% of Vertex Planning Partners's portfolio in Q2 2026, its #25 holding.
Vertex Planning Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Vertex Planning Partners's 13F filing for Q2 2026, filed 14 Aug 2026.